nerandomilast
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
Mechanism of action
- inhibitor of phosphodiesterase 4B
- antifibrotic & immunomodulatory properties
More general terms
References
- ↑ 1.0 1.1 Maher TH, Assassi S, Azuma A et al Nerandomilast in Patients with Progressive Pulmonary Fibrosis N Engl J Med. 2025 Jun 12;392(22):2203-2214 PMID: https://pubmed.ncbi.nlm.nih.gov/40388329 Clinical Trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2503643